{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "exchange": "HKG", "shortName": "ASCLETIS-B", "longName": "Ascletis Pharma Inc.", "messageBoardId": "finmb_574413177", "market": "hk_market", "marketState": "CLOSED", "earningsTimestamp": 1679268622, "earningsTimestampStart": 1679268622, "earningsTimestampEnd": 1679268622, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.32, "epsForward": -0.08, "epsCurrentYear": -0.1, "priceEpsCurrentYear": -25.0, "sharesOutstanding": 1087129984, "bookValue": 2.336, "fiftyDayAverage": 2.7708, "fiftyDayAverageChange": -0.2708001, "fiftyDayAverageChangePercent": -0.09773354, "twoHundredDayAverage": 3.2874, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "esgPopulated": false, "regularMarketChangePercent": -4.5801487, "regularMarketPrice": 2.5, "regularMarketChange": -0.119999886, "regularMarketTime": 1683878353, "regularMarketDayHigh": 2.65, "regularMarketDayRange": "2.46 - 2.65", "regularMarketDayLow": 2.46, "regularMarketVolume": 1111000, "regularMarketPreviousClose": 2.62, "bid": 2.49, "ask": 2.5, "bidSize": 0, "askSize": 0, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 2.65, "averageDailyVolume3Month": 1454524, "averageDailyVolume10Day": 995800, "fiftyTwoWeekLowChange": 0.5, "fiftyTwoWeekLowChangePercent": 0.25, "fiftyTwoWeekRange": "2.0 - 5.46", "fiftyTwoWeekHighChange": -2.96, "fiftyTwoWeekHighChangePercent": -0.54212457, "fiftyTwoWeekLow": 2.0, "fiftyTwoWeekHigh": 5.46, "twoHundredDayAverageChange": -0.7874, "twoHundredDayAverageChangePercent": -0.2395206, "marketCap": 2717825024, "forwardPE": -31.25, "priceToBook": 1.0702055, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "3.0 - Hold", "firstTradeDateMilliseconds": 1533087000000, "priceHint": 3, "symbol": "1672.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building D", "address2": "12th Floor 198 Qidi Road, HIPARK Xiaoshan District", "city": "Hangzhou", "country": "China", "phone": "86 571 8538 9730", "website": "https://www.ascletis.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.", "fullTimeEmployees": 278, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jinzi Jason  Wu Ph.D.", "age": 58, "title": "Founder, Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 3266662, "fmt": "3.27M", "longFmt": "3,266,662"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Hejingdao  Wu", "age": 47, "title": "Sr. VP of Operations & Exec. Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 385768, "fmt": "385.77k", "longFmt": "385,768"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Handan  He Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Yuemei  Yan", "age": 52, "title": "Sr. VP of Clinical Devel. Operations", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kristjan Sigurdur Gudmundsson", "age": 54, "title": "Sr. Consultant & Head of Discovery", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. George Zhengzhi Hill", "age": 71, "title": "Sr. Consultant & Chief Medical Advisor", "yearBorn": 1951, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John P. Gargiulo M.B.A.", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ming Fai  Chung CPA", "age": 43, "title": "Company Sec.", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}